MedTrace Logo

Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy

NCT00683189 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2011-03-21

No results posted yet for this study

Summary

Objectives/Purpose:

To determine the safety and efficacy of a Vitamin K (Vit K) antagonist (warfarin) in treating Metachromatic Leukodystrophy (MLD).

Conditions

  • Metachromatic Leukodystrophy

Interventions

DRUG

Warfarin

Oral administration (QD), variable dosage: patients will undergo blood test for PT/INR at baseline and afterwards, at weekly bases for 4 weeks. The INR will be kept in a safe range of 2-2.5

Sponsors & Collaborators

  • The Cooper Health System

    lead OTHER

Principal Investigators

  • Paola Leone, Ph.D. · UMDNJ/SOM

  • Mitra Assadi, M.D. · The Cooper Health System

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2008-05-31
Completion
2008-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00683189 on ClinicalTrials.gov